tiprankstipranks
Acorda Therapeutics sees FY23 revenue $122.2M – $135M
The Fly

Acorda Therapeutics sees FY23 revenue $122.2M – $135M

The revised guidance also reflects updates from actual financial results from October and November 2022 and from the Company’s year-end budgeting process. These updates include the Company’s projected sales of Inbrija outside the United States and total Inbrija sales for 2024-2027. The revised long-term financial guidance does not affect Acorda’s previously reported financial results for the period ended September 30, 2022 or Inbrija U.S. net revenue guidance for 2022 of between $27.8 – $28.7 million.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on ACOR:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles